Positive airway pressure therapy may delay cognitive decline in sleep apnea patients

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-05-19 05:15 GMT   |   Update On 2022-05-19 07:42 GMT

USA: Results from a systematic review published in the journal Neurology showed that in adults with obstructive sleep apnea (OSA), positive airway pressure (PAP) therapy may delay cognitive decline, however, further research is needed. Alzheimer's disease (AD) and other dementia forms represent a rising global public health crisis. Owing to the unavailability of treatments to prevent, cure,...

Login or Register to read the full article

USA: Results from a systematic review published in the journal Neurology showed that in adults with obstructive sleep apnea (OSA), positive airway pressure (PAP) therapy may delay cognitive decline, however, further research is needed. 

Alzheimer's disease (AD) and other dementia forms represent a rising global public health crisis. Owing to the unavailability of treatments to prevent, cure, or slow dementia progression, promising means to modify dementia occurrence or severity could be the identification of treatable risk factors that increase dementia risk, such as OSA. 

Against the above background, Monica Moon Shieu, University of Michigan, Department of Neurology, Division of Sleep Medicine, and colleagues systematically reviewed the impact of PAP therapy on the incidence of cognitive disorders and cognitive decline among middle-aged and older adults with OSA. 

Based on the findings, the researchers found the following:

· Eleven studies (three clinical trials and eight observational studies) were identified.

· In these studies, 96% participants had OSA (n= 60,840) and n=5,826 had baseline cognitive impairment (mild cognitive impairment [MCI] or AD).

· Of all study participants, n=43,973 obtained PAP therapy, and n=16,397 were untreated or in a placebo group.

· Most studies reported a protective effect of PAP therapy on MCI and AD incidence, e.g., delayed age at MCI onset, reduced MCI or AD incidence, slower cognitive decline, or progression to AD.

"These findings suggest the role of OSA as a modifiable risk factor for cognitive decline. The burden of cognitive disorders on aging adults and their families calls for modifiable risk factors to reduce their impact among adults and their families."

"Future researcher that focuses on PAP interventions as a potential means to alleviate the incidence of cognitive disorders and cognitive decline is needed, particularly among ethnoracial minority groups who have been underrepresented and under-investigated in the extant literature," they concluded.

Reference:

Positive Airway Pressure and Cognitive Disorders in Adults With Obstructive Sleep Apnea: A Systematic Review of the Literature Monica Moon Shieu, Afsara Zaheed, Carol Shannon, Ronald David Chervin, Alan Conceicao, Henry Lauris Paulson, Tiffany Joy Braley, Galit Levi Dunietz Neurology May 2022, 10.1212/WNL.0000000000200383; DOI: 10.1212/WNL.0000000000200383

Tags:    
Article Source : Neurology journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News